John Wiley & Sons Limited
Все книги издательства John Wiley & Sons Limited
Digital Transformations in the Challenge of Activity and Work
TECHNOLOGICAL CHANGES AND HUMAN RESOURCES SET Coordinated by Patrick Gilbert The accelerating pace of technological change (AI, cobots, immersive reality, connected objects, etc.) calls for a profound reexamination of how we conduct business. This requires new ways of thinking, acting, organizing and collaborating in our work. Faced with these challenges, the Human and Social Sciences have a leading role to play, alongside others, in designing, supporting and implementing these digital transformation projects. Their ambition is to participate in the development of innovative and empowering devices, that is to say, systems that are truly at the service of human beings and their activity, that empower these professionals to take action and that also provide occupational health services. This book takes a multidisciplinary look at the challenges of these digital transformations, making use of occupational psychology, ergonomics, sociology of uses, and management sciences. This viewpoint also helps provide epistemological, methodological and empirical insights to better understand and support the changes at work.
Speech Acoustic Analysis
The text sets out in simple and accessible terms the various methods of acoustic analysis of speech, placing them in their historical context, allowing a better understanding of the mathematical and technical solutions adopted today in phonetics and experimental phonology. Without mathematical complications, the operating bases of the many speech analysis software currently available are exposed so that everyone can understand the limits and avoid errors and misinterpretations in their implementation.
Biologics, Biosimilars, and Biobetters
A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective.<br /><br /> <ul> <li>Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about</li> <li>Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence</li> <li>Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists</li> </ul>